Description: NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Home Page: immunitybio.com
IBRX Technical Analysis
3530 John Hopkins Court
San Diego,
CA
92121
United States
Phone:
858 633 0300
Officers
| Name | Title |
|---|---|
| Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc. | Exec. Chairman, Global Chief Scientific & Medical Officer |
| Mr. Richard Gerald Adcock | Pres, CEO & Director |
| Mr. David C. Sachs | CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Leonard S. Sender M.D. | Chief Operating Officer |
| Mr. Jason R. Liljestrom | Gen. Counsel & Corp. Sec. |
| Ms. Sarah Singleton | Chief Communications Officer |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
| Dr. Barry J. Simon M.D. | Chief Corp. Affairs Officer & Director |
| Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular |
| Ms. Helen Luu | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 4822.3335 |
| IPO Date: | 2015-07-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 760 |